Following the completion of its acquisition by Novartis, Avidity Biosciences stock (formerly trading under the NASDAQ ticker RNA) was delisted from public exchanges as part of the transaction process. Consequently, retail investors can no longer purchase shares of the company directly on public markets. Investors seeking exposure to the biopharmaceutical sector must evaluate alternative publicly traded biotech enterprises and pharmaceutical equities.